Phase I Study of Th-1 Dendritic Cell Immunotherapy in Combination With Standard Chemotherapy for the Adjuvant Treatment of Pancreatic Adenocarcinoma (DECIST)
Summary
The primary objective of this phase I, first in man trial is to determine the safety, toxicity, and feasibility of delivering autologous dendritic cells (DCs) loaded with pancreatic adenocarcinoma lysate plus mRNA to pancreatic cancer patients as adjuvant therapy following completion of standard chemotherapy.
General Information
NCT#: NCT04157127
Study ID: H-42434
Trial Phase: Phase I
Trial Sponsor: Baylor Research Institute
Therapies Used in This Trial: Dendritic Cell (DC) vaccine, PEG interferon alpha-2b